- Home
- MBAI vs CNTX Comparison
MBAI vs CNTX Comparison
Compare MBAI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBAI | CNTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 47.7M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBAI | CNTX |
|---|---|---|
| Price | $2.29 | $0.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.14 |
| AVG Volume (30 Days) | 24.4K | ★ 1.2M |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.86 | N/A |
| Revenue Next Year | $231.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.18 |
| 52 Week High | $10.21 | $3.62 |
Technical Indicators
Market Signals| Indicator | MBAI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 32.42 |
| Support Level | $1.33 | N/A |
| Resistance Level | $2.64 | $0.36 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 65.55 | 26.96 |
Price Performance
Historical ComparisonAbout MBAI Check-Cap Ltd. Ordinary Share
MBody AI Ltd develops enterprise software to deploy and manage autonomous robot workforces for hospitality and gaming operators. The Company's proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI serves Fortune 500 operators as customers.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.